Department：Breast Surgery
Medical School: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, USA
Academic Rank：Associate Chief Physician
Prevention, diagnosis and treatment of breast cancer, breast conservation surgery, breast reconstruction, mastectomy, sentinel lymph node biopsy, lumpectomy, and benign breast tumors.
Zhejiang Scientific and Technological Progress Award, First Prize, 2009
Youth Committee Member, Chinese Society of Oncology, 2018-present
Vice Chair, Youth Committee, Zhejiang Society of Oncology, 2016-present
Dr. Hu's research focuses on: 1. screening, validation and function of tumor marker candidates of breast cancer; 2. metabonomics of breast cancer; 3. translational research of breast cancer; 4. innovation and creation of surgical instruments.
Hu Y*, Qiu JL, Zhou MQ, Li XZ, Huang YQ. LAP2alpha, a novel tumor marker candidate is related to metastasis of breast cancer. Cancer Res, 2019, 79(4 Suppl): P2-01-20.
Hu Y*, Feit N, Huang YQ, Xu WH, Zheng S, Li XZ*. Gastrointestinal metastasis of primary lung cancer: An analysis of 366 cases. Oncol Lett, 2018, 15(6): 9766-9776.
Thakar M, Hu Y, Morreale M, Lerner L, Ying Lin W, Sen R, Cai Y, Karunasena E, Thakar M, Saggi S, Keer H, Ahuja N*. A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent. PLoS One, 2018, 13(6): e0199130.
De Carvalho Fischer C, Hu Y, Morreale M, Lin WY, Wali A, Thakar M, Karunasena E, Sen R, Cai Y, Murphy L, Zahnow CA, Keer H, Thakar M*, Ahuja N*. Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma. Oncotarget, 2018, 9(27): 19379-19395.
Hu Y, Thakar M, Saggi S, Ahuja N*. Guadecitabine (SGI110) Sensitizes Pancreatic Cell Lines to Irinotecan Treatment. Ann Surg Oncol, 2017, 24(Suppl 1): PF244.
Li XF, Huang YQ, Hu Y*. Inhibition of LAP2α can suppress cell aggressiveness in breast cancer. Ann Oncol, 2016, 27(suppl 9): 48P.
Hu Y*, Li XZ, Deng YC, Zhou MQ, Zhang SZ. Primary malignant fibrous histiocytoma of the breast: a case report and review of 38 Chinese cases. Clin Breast Cancer, 2012, 12(5): 382-385.
Hu Y, Zhang SZ*, Yu JK, Liu J, Zheng S. SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast, 2005, 14(4): 250-255.
Systemic Research on LAP2a, a Tumor Marker Candidate of Breast Cancer. Funding Source: Natural Science Foundation of Zhejiang (LY14H160030).
Metabolic Mechanism of Heterogenicity of Cancer. Funding Source: State Key Development Program of Basic Research of China (973 Program, 2014CB542003).
88 Jiefang Road,Shangcheng District Hangzhou,China, 310009
1511 Jianghong Road,Binjiang District Hangzhou,China, 310014
300 Yuanju Road, Shangcheng DIstrict, Hangzhou
456 Qidi Road, Xiaoshan District, Hangzhou, China
1 Xihu Avenue, Shangcheng District, Hangzhou
Zijingang Campus of Zhejiang University, 866 Yuhangtang Road, Xihu District, Hangzhou
Please call +86-571-8971 3988 (8am-5pm, Monday through Friday)
Make an appointment online
The Second Affiliated Hospital
Zhejiang University School of Medicine
88 Jiefang Road, Hangzhou, China
+86-571-8731 5108
iao_sahzu@zju.edu.cn
The Needs of Patients and Customers Come First.
The Second Affiliated Hospital Zhejiang University School of Medicine
All Rights Reserved.
